Jinghua Wang1, Weida Wang2, Hao Chen3, Wenmin Li4, Tian Huang1, Weiya Zhang1, Wei Ling1, Peilong Lai1, Yulian Wang1, Suxia Geng1, Minming Li1, Xin Du1, Jianyu Weng1. 1. Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 2. Department of Hematology Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. 3. Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. 4. Department of Laboratory Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Abstract
OBJECTIVE: AML is a heterogeneous disease both in genomic and proteomic backgrounds, and variable outcomes may appear in the same cytogenetic risk group. Therefore, it is still necessary to identify new antigens that contribute to diagnostic information and to refine the current risk stratification. METHODS: The expression of C-type lectin-like molecule-1 (CLL-1) in AML blasts was examined in 52 patients with newly diagnosed or relapsed/refractory AML and was compared with two other classic markers CD33 and CD34 in AML, in order to assess the value of CLL-1 as an independent biomarker or in combination with other markers for diagnosis in AML. Subsequently, the value of CLL-1 as a biomarker for prognosis was assessed in this malignant tumor. RESULTS: The results showed that CLL-1 was expressed on the cell surface of the majority of AML blasts (78.8%) and also expressed on leukemic stem cells in varying degree but absent on normal hematopoietic stem cells. Notably, CLL-1 was able to complement the classic markers CD33 or CD34. After dividing the cases into CLL-1high and CLL-1low groups according to cutoff 59.0%, we discovered that event-free survival and overall survival (OS) of the CLL-1low group were significantly lower than that of the CLL-1high group, and low CLL-1 expression seems to be independently associated with shorter OS. CONCLUSIONS: These preliminary observations identified CLL-1 as a biomarker for diagnosis and prognosis of AML.
OBJECTIVE: AML is a heterogeneous disease both in genomic and proteomic backgrounds, and variable outcomes may appear in the same cytogenetic risk group. Therefore, it is still necessary to identify new antigens that contribute to diagnostic information and to refine the current risk stratification. METHODS: The expression of C-type lectin-like molecule-1 (CLL-1) in AML blasts was examined in 52 patients with newly diagnosed or relapsed/refractory AML and was compared with two other classic markers CD33 and CD34 in AML, in order to assess the value of CLL-1 as an independent biomarker or in combination with other markers for diagnosis in AML. Subsequently, the value of CLL-1 as a biomarker for prognosis was assessed in this malignant tumor. RESULTS: The results showed that CLL-1 was expressed on the cell surface of the majority of AML blasts (78.8%) and also expressed on leukemic stem cells in varying degree but absent on normal hematopoietic stem cells. Notably, CLL-1 was able to complement the classic markers CD33 or CD34. After dividing the cases into CLL-1high and CLL-1low groups according to cutoff 59.0%, we discovered that event-free survival and overall survival (OS) of the CLL-1low group were significantly lower than that of the CLL-1high group, and low CLL-1 expression seems to be independently associated with shorter OS. CONCLUSIONS: These preliminary observations identified CLL-1 as a biomarker for diagnosis and prognosis of AML.
Authors: Chang-Hung Chen; Helen Floyd; N Eric Olson; Dario Magaletti; Chang Li; Kevin Draves; Edward A Clark Journal: Blood Date: 2005-10-20 Impact factor: 22.113
Authors: Valerie R Wiersma; Marco de Bruyn; Ce Shi; Marloes J M Gooden; Maartje C A Wouters; Douwe F Samplonius; Djoke Hendriks; Hans W Nijman; Yunwei Wei; Jin Zhou; Wijnand Helfrich; Edwin Bremer Journal: MAbs Date: 2015 Impact factor: 5.857
Authors: Andrew S J Marshall; Janet A Willment; Hsi-Hsien Lin; David L Williams; Siamon Gordon; Gordon D Brown Journal: J Biol Chem Date: 2004-01-22 Impact factor: 5.157
Authors: A van Rhenen; B Moshaver; A Kelder; N Feller; A W M Nieuwint; S Zweegman; G J Ossenkoppele; G J Schuurhuis Journal: Leukemia Date: 2007-05-24 Impact factor: 11.528
Authors: Anna van Rhenen; Guus A M S van Dongen; Angèle Kelder; Elwin J Rombouts; Nicole Feller; Bijan Moshaver; Marijke Stigter-van Walsum; Sonja Zweegman; Gert J Ossenkoppele; Gerrit Jan Schuurhuis Journal: Blood Date: 2007-07-03 Impact factor: 22.113
Authors: S Haubner; F Perna; T Köhnke; C Schmidt; S Berman; C Augsberger; F M Schnorfeil; C Krupka; F S Lichtenegger; X Liu; P Kerbs; S Schneider; K H Metzeler; K Spiekermann; W Hiddemann; P A Greif; T Herold; M Sadelain; M Subklewe Journal: Leukemia Date: 2018-06-26 Impact factor: 11.528